CompletedPhase 2NCT03334058
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
Studying Pemphigus foliaceus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Principal Investigator
- Patrick Dupuy, MD, ODargenx
- Intervention
- ARGX-113(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (12)
- University of Lübeck and UKSH, Department of Dermatology and Lübeck Institute of Experimental Dermatology, Lübeck, Germany
- Clinic of Dermatology and Allergology - Philipps University Marburg, Marburg, Germany
- University of Debrecen Medical Center Department of Dermatology, Debrecen, Hungary
- University of Pécs Clinical Center , Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary
- University of Szeged Faculty of Medicine Albert Szent-Györgyi Medical Center Department of Dermatology and Allergology, Szeged, Hungary
- HaEmek Medical center, Dermatology Department, Afula, Israel
- Department of Dermatology, The Chaim Sheba Medical Center, Tel Aviv, Israel
- Department of dermatology, The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Dermopathic Institute of the Immaculate - Foundation "Luigi Maria Monti", Rome, Italy
- Foundation Policlinico A. Gemelli - Dermatology Department, Rome, Italy
- National Medical University named after O.O.Bohomolets, Department of Dermatology and Venereology based on Oleksandrivska Clinical Hospital of Kyiv City, Department of Dermatology, Kyiv, Ukraine
- Municipal Institution "Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary" of Zaporizhzhya Regional Council, Zaporizhzhya, Ukraine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03334058 on ClinicalTrials.gov